FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medications and deals with pharmaceutical composition for treatment of cardio-vascular diseases, which contains in effective quantity hydroxylated metabolite of nebivolol or its pharmaceutically acceptable salt and pharmaceutical acceptable carrier.
EFFECT: compositions by invention ensure increased release of NO in endothelial cells 
.
11 cl, 18 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| GLUCURONIDATED NEBIVOLOL METABOLITES | 2006 |
|
RU2413518C2 |
| COMPOSITIONS CONTAINING NEBIVOLOL | 2010 |
|
RU2593335C2 |
| COMPOSITIONS CONTAINING NEBIVOLOL | 2005 |
|
RU2441653C2 |
| PHARMACEUTICAL COMPOSITION ELICITING IMPROVED ANTITUMOR EFFECT AND/OR REDUCED ADVERSE EFFECTS AND COMPRISING ANTITUMOR AGENT AND DERIVATIVE OF HYDROXAMIC ACID | 1998 |
|
RU2254129C2 |
| 19,11-BRIDGED OVER 4-ESTRENES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, INTERMEDIATE COMPOUNDS | 1993 |
|
RU2157814C2 |
| METHOD OF PRODUCING DERIVATIVES OF DELTA 4-9-19-NORSTEROIDS | 0 |
|
SU1340593A3 |
| TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2833354C1 |
| CONDENSED HETEROCYCLIC SUCCINAMIDE COMPOUNDS | 2001 |
|
RU2298554C2 |
| METHOD FOR THE SYNTHESIS OF STEROID, SUBSTITUTED WITH SPIRANE CYCLE | 0 |
|
SU1715205A3 |
| TLR7 AGONISTS | 2019 |
|
RU2817014C2 |
